Do Post-Market Drug Trials Need a Higher Dose of Ethics?

Patients who sign up for trials testing more than one already approved intervention do not always know if one is being tested for harmful side effects

By Katherine Harmon

Uninformed consent?: Some trials performed after treatments are approved fail to inform participants that one or more of the treatments being tested might have more serious side effects than they realize. Image: iStockphoto/monkeybusinessimages

Say you have high blood pressure. There's a new blockbuster drug on the market, and your doctor lets you know about a new clinical trial you can join that is testing the new treatment against an old tried-and-true one. What's not to like? You're going to be taking, under the care of experts, one of two U.S. Food and Drug Administration?approved medications.

What you might not know?even after you sign up for the trial and have inked the informed-consent form?is that scattered reports are starting to suggest that the new medication might occasionally cause severe side effects. And the real reason the trial is being conducted with these previously released drugs is to test whether the new medication really is a lot riskier to everyone or just to a subset of patients.

If you found that out, would you still sign up for the trial? The problem is that many patients?and often even the institutional review boards that approve the trials?are never informed of these lingering questions.

This is one of the big ethical holes often left open in post-market trials, says Ruth Faden, director of the Johns Hopkins Berman Institute of Bioethics, who co-authored a new essay on this topic in The New England Journal of Medicine, which was published online August 22. She and a team of co-authors released a formal Institute of Medicine (IOM) report earlier this year recommending that the FDA improve this and other ethical aspects of post-market trials?especially those it requires.

This issue hit the headlines two years ago, when the FDA suddenly restricted the use of Avandia, a drug that had been approved to treat diabetes.? It had become clear that patients in post-market trials were at increased risk for heart attack and stroke?risks about which drugmaker GlaxoSmithKline knew but had not informed patients.

When patients sign up for clinical trials to test an experimental drug, procedure or device, they give their informed consent after doctors counsel them about the risks and uncertainty associated with a not-yet-approved intervention. Volunteers are often more than willing to accept those risks if the experimental intervention offers potentially more promising treatment for their condition, compared with what is on the market.

The benefits of signing up for a trial testing a drug that is already on the market are less clear. Patients and their doctors will already have the option to choose that same drug without being part of a study, ideally taking any known risks into consideration. If they sign up for a trial, however, they will be randomized into groups and required to take one of the test therapies?especially if one is suspected to cause occasional severe side effects?"Now you've got this heightened ethical obligation toward these people," Faden says. "They need to understand why this particular trial is being conducted." This step is often lacking in post-market trials, especially those conducted by the pharmaceutical companies and their contractors, she notes.

With so many new therapies being fast-tracked through the FDA approval process, post-release vigilance is becoming increasingly important, Faden and her colleagues noted in the piece. And when suspicion arises that a new medication might be causing more harm than it is worth, a large, formal, randomized controlled clinical trial is necessary. But informing patients fully of the risks they are taking is ethically imperative, the researchers concluded. "That's a hard sell," but potential trial participants would need to knowingly shoulder the risks to hopefully help others down the road.

Source: http://rss.sciam.com/click.phdo?i=b05bbde7a3016927293f5ff1aa04fe97

oberon donald driver donald driver robin thicke mariana trench transcendental meditation trayvon martin